Jenene Thomas
Jenene Thomas Communications, LLC
Okay. We are ready to get started. So good afternoon, everyone, and thank you for joining us today for our Virtual Investor Closing Bell segment. My name is Jenene Thomas, I am CEO of JTC IR, and I will be the moderator. So today, we are featuring Decoy Therapeutics, and I am very pleased to be joined by Rick Pierce. He is Chief Executive Officer of the company. Welcome, Rick.
Frederick Pierce
CEO & Director
Good afternoon, everybody, and pleasure to be here, Jenene.
Jenene Thomas
Jenene Thomas Communications, LLC
Well, we are so happy to have you, and we’re really excited to showcase Decoy today on our platform and to provide investors the opportunity to connect with you. So for today’s event, we’ll start with an overview of Decoy from Rick, and we will follow that by a Q&A for myself and the audience.
And before we get started, I just want to remind our audience that Decoy Therapeutics is publicly listed on Nasdaq and trades under the ticker DCOY. And during today’s discussion, the company will be making forward-looking statements, and I encourage everyone to view the company’s latest SEC filings on their website at decoytx.com for the latest information.
So Rick, we’ve been really looking forward to having on our platform. We saw your press release today. A lot to talk about, but I think you’re fairly new to the virtual investor platform. We’d love for you to walk through the story. So I’m going to turn it over to you.
